Anti-apoptotic effects of human placental hydrolysate against hepatocyte toxicity in vivo and in vitro

DONG-HO BAK1,2*, JUNGTAE NA1*, MI JI CHOI1,2*, BYUNG CHUL LEE1, CHANG TAEK OH3, JEOM-YONG KIM3, HAE JUNG HAN3,4, MOO JOONG KIM5, TAE HO KIM6 and BEOM JOON KIM1,2

1Department of Dermatology, College of Medicine; 2Department of Medicine, Graduate School, Chung-Ang University, Seoul 06973; 3Research and Development Center, Green Cross WellBeing Corporation, Seongnam, Gyeonggi 13595; 4Department of Microbiology and Medical Research Institute, Chungbuk National University, College of Medicine, Cheongju, Chungcheongbuk 28644, Republic of Korea; 5Fort Hays State University, Hays, KS 67601, USA; 6Division of Gastroenterology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, The Catholic University of Korea, Bucheon-si, Gyeonggi 14647, Republic of Korea

Received April 15, 2018; Accepted July 30, 2018

DOI: 10.3892/ijmm.2018.3830

Abstract. Apoptosis and oxidative stress are essential for the pathogenesis of acute liver failure and fulminant hepatic failure. Human placental hydrolysate (hPH) has been reported to possess antioxidant and anti-inflammatory properties. In the present study, the protective effects of hPH against d-galactosamine (d-GalN)- and lipopolysaccharide (LPS)-induced hepatocyte apoptosis were investigated in vivo. In addition, the molecular mechanisms underlying the anti-apoptotic activities of hPH against D-GalN-induced cell death in vitro were examined. Male Sprague-Dawley rats were injected with D-GaIN/LPS with or without the administration of hPH. Rats were sacrificed 24 h after D-GaIN/LPS intraperitoneal injection, and the blood and liver samples were collected for future inflammation and hepatotoxicity analyses. Changes in cell viability, apoptosis protein expression, mitochondrial mass, mitochondrial membrane potential, reactive oxygen species generation, and the levels of proteins and mRNA associated with a protective mechanism were determined in HepG2 cells pretreated with hPH for 2 h prior to D-GaIN exposure. The findings suggested that hPH treatment effectively protected against D-GalN/LPS-induced hepatocyte apoptosis by reducing the levels of alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, interleukin-6, and tumor necrosis factor-α, and increasing the level of proliferating cell nuclear antigen. It was also found that hPH inhibited the apoptotic cell death induced by D-GalN. hPH activated the expression of antioxidant enzymes, including superoxide dismutase, glutathione peroxidase, and catalase, which were further upregulated by the Kelch-like ECH2-associated protein 1-p62-nuclear factor-erythroid 2-related factor 2 pathway, a component of oxidative stress defense mechanisms. Furthermore, hPH markedly reduced cytosolic and mitochondrial reactive oxygen species and rescued mitochondrial loss and dysfunction through the reduction of damage-regulated autophagy modulator, p53, and C/EBP homologous protein. Collectively, hPH exhibited a protective role in hepatocyte apoptosis by inhibiting oxidative stress and maintaining cell homeostasis. The underlying mechanisms may be associated with the inhibition of endoplasmic reticulum stress and minimization of the autophagy progress.

Introduction

Acute liver failure (ALF), sometimes referred to as fulminant hepatic failure, is a severe liver disease characterized by coagulopathy and liver inflammation in patients with previously normal liver function (1). The onset of liver injury, often accompanied by endotoxemia and hepatocyte death, can result in high mortality rates in animals and humans, due to the lack of an effective therapy for ALF, other than liver transplantation (2).

The administration of D-galactosamine (D-GaIN) and lipopolysaccharides (LPS) establishes an animal model for ALF; it severely impairs liver function in laboratory animals, and can be used to investigate ALF (3). LPS, a type of endotoxin, can cause liver tissue damage through activation of inflammatory cytokines, including interleukin (IL)-1β, IL-6,
tumor necrosis factor (TNF)-α, and interferon-γ (4). A report suggests that LPS as an inflammatory mediator can stimulate the production of reactive oxygen species (ROS) and can be used broadly to induce research models of ALF (5). A D-GalN/LPS-induced animal model of ALF is representative of human liver failure and has been widely used to investigate mechanisms and potential therapeutic drugs for clinical use in treating ALF (2). Increasing evidence has shown that oxidative stress and hepatocyte apoptosis are two important pathogenic factors that contribute to D-GalN/LPS-induced ALF (6,7).

The evaluation of mechanisms involved in D-GalN/LPS-induced hepatic apoptosis has indicated that mitochondria are critical targets for drug toxicity through the formation of reactive metabolites (8,9). In response to oxidative stress, the cellular machinery of the antioxidative response is mediated by cytoprotective enzymes in the liver. When it comes to oxidation, nuclear factor-E2-related factor 2 (Nrf2), a key sensor in antioxidative stress systems, regulates cellular defense against oxidative damage (10), contributing to diverse cellular functions, including proliferation, inflammation and lipid synthesis (11). The aberrant expression or function of Nrf2 has been linked to pathologies, including hepatic steatosis (12) and diabetic nephropathy (13). Although Nrf2 is regularly sequestered by Kelch-like ECH2-associated protein 1 (Keap1) in the cytoplasm (14), when activated, it translocates into the nucleus and upregulates antioxidant response element (ARE) genes, including superoxide dismutase (SOD)1/2, catalase, glutamate-cysteine ligase catalytic subunit (GCLC), glutamate-cysteine ligase regulatory subunit (GCLM), heme oxygenase-1 (HO-1), cytochrome P450s, multidrug-resistant proteins and NAD(P)H dehydrogenase quinone 1 (NQO1) (15,16).

In general, the autophagy-dependent degradation of impaired organelles, including the selective degradation of the endoplasmic reticulum (ER; reticulophagy), mitochondria (mitophagy), and lipid droplets (lipophagy), is a crucial cellular pathway for maintaining cell homeostasis (17,18). However, autophagy is also regarded as a pro-apoptotic factor and causes ‘type II’ programmed cell death (19). The cellular damage mediated by p53 has a pathological role in the progression of hepatosteatosis. It is noteworthy that p53 can promote the expression of damage-regulated autophagy modulator (DRAM), an inducer of autophagy-mediated apoptosis (20).

Previous studies have revealed that human placental hydrolysate (hPH) is a rich source of various bioactive substances, including polydeoxyribonucleotides, RNA, DNA, peptides, amino acids, enzymes, and trace elements, among others (21). Human placenta has been demonstrated to possess various therapeutic properties ranging from wound healing to immunomodulation (22). The use of aqueous extract of human placenta for intervention in different diseases, the present study was undertaken to investigate the protective effects of hPH against apoptotic hepatocyte cell death in vivo and in vitro.

Materials and methods

Reagents and antibodies. All chemicals and solvents used were of the highest analytical grade available. Cell culture supplies and media, including fetal bovine serum (FBS), phosphate-buffered saline (PBS), and penicillin-streptomycin were purchased from Thermo Fisher Scientific, Inc. (Waltham, MA, USA). The Cell Counting Kit-8 (CCK-8; cat. no. CK04-11) was from Dojindo Molecular Laboratories, Inc. (Kumamoto, Japan). Protease inhibitor cocktail (cat. no. P8340) and D-GalN (cat. no. G0500) were purchased from Sigma-Aldrich; EMD Millipore (Billerica, MA, USA). Anti-proliferating cell nuclear antigen (PCNA; cat. no. ab15497), anti-Tomm20 (cat. no. ab56783) and anti-Lamin B1 (cat. no. ab16048) antibodies were purchased from Abcam (Cambridge, UK). Anti-poly (ADP) ribose polymerase (PARP; cat. no. 9532S) antibody was purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA). Anti-B-cell lymphoma 2 (BCL2; cat. no. SC-7382), anti-Bcl-2-associated X protein (BAX; cat. no. SC-526), anti-DRAM (cat. no. SC-81713), anti-SOD1 (cat. no. SC-17767), anti-SOD2 (cat. no. SC-130345), anti-glutathione peroxidase (GPX; cat. no. SC-133160), anti-Catalase (cat. no. SC-271358), anti-Keap1 (cat. no. SC-365626), anti-HO-1 (cat. no. SC-136960), anti-p53 (cat. no. SC-126), anti-GAPDH (cat. no. SC-20357), and anti-Nrf2 (cat. no. SC-81342) antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Anti-microtubule-associated protein 1A/1B-light chain 3 (LC3)I/II (cat. no. PM036), anti-phosphorylated-p62 (cat. no. PM074), and anti-p62 (cat. no. PM045) antibodies were purchased from MBL International Corporation (Woburn, MA, USA). hPH (Laennec inj.) was manufactured by Green Cross WellBeing Corporation (Seongnam, Korea) through the hydrolysis of human placenta with HCl and pepsin.

Animals and experimental design. Sprague-Dawley rats (SD) rats (male, 6-8 weeks old, weighing ~200-250 g each) were purchased from Raonbio, Inc. (Yongin, Korea). These rats were provided with adequate food and water ad libitum and were housed in clean cages for 1 week. The laboratory temperature was 24±1°C and relative humidity was 40-80%. All animal experiments were performed according to the Guide for the Care and Use of Laboratory Animals as published by the US National Institutes of Health. The present study was reviewed and approved by the Animal Welfare and Research Ethics Committee at Chung-Ang University (Seoul, Korea; 2017-00003). Acute liver injury was induced by intraperitoneal injection of LPS (15 µg/kg) together with D-GalN (700 mg/kg) dissolved in normal saline, which can increase the sensitivity of hepatocytes. Blood was collected from the inferior vena cava 24 h following injection of D-GalN/LPS. The SD rats were then dissected, and liver tissues were removed immediately for histological detection. Normal PBS was used in control rats. hPH (1.2, 2.4, and 3.6 ml/kg) was injected subcutaneously into each mouse 24, 48, and 72 h prior to D-GalN/LPS injection. As a negative control, only D-GalN/LPS was injected.
Evaluation of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST). The collected blood samples were stored overnight at 4°C. The serum was isolated the subsequent day following centrifugation at 15,928 x g for 10 min at 4°C. The ALT and AST were detected using a Hitachi 7600 Series automatic biochemical analyzer (Hitachi, Ltd., Tokyo, Japan).

Enzyme-linked immunosorbent assay (ELISA) of cytokines. Based on a previous study, blood was collected for measuring TNF-α (cat. no. 438207) and IL-6 (cat. no. 437107) at 24 h post-D-GalN/LPS injection. The serum was separated by centrifugation at 15,928 x g at 4°C for 10 min. The cytokines were measured using mouse ELISA kits (BioLegend, Inc., San Diego, CA, USA) according to the manufacturer's protocol.

Histopathological evaluation. The liver tissues were immersed in normal 10% neutral buffered formalin and fixed for 48 h, dehydrated in a series of graded ethanol, embedded in paraffin wax, and cut into 5-µm sections. The paraffin-embedded sections were stained with hematoxylin and eosin (H&E) for pathological analysis under a light microscope. Histological changes were evaluated using a point-counting method for the severity of hepatic injury using an ordinal scale, as previously described (27). Briefly, the H&E-stained sections were evaluated at x400 magnification using the point-counting method for the severity of hepatic injury with an ordinal scale as follows: grade 0, minimal or no evidence of injury; grade 1, mild injury consisting of cytoplasmic vacuolation and focal nuclear pyknosis; grade 2, moderate to severe injury with extensive nuclear pyknosis, cytoplasmic hyperterosinophilia, and loss of intercellular borders; and grade 3, severe necrosis with disintegration of hepatic cords, hemorrhage, and neutrophil infiltration.

Measurement of apoptosis via TUNEL assay. TUNEL was performed to analyze DNA fragmentation indicative of cellular apoptosis using the in situ cell death detection kit (cat. no. ab206386, Abcam), according to the manufacturer's protocol. The paraffin wax-embedded tissue sections were treated with proteinase K, and endogenous peroxidase activity was blocked with hydrogen peroxide. The sections were incubated at 37°C with the terminal TdT nucleotide mixture for 1 h. The reactions were then terminated, and the slides were rinsed with PBS. Nuclear labeling was developed with horseradish peroxidase and diaminobenzidine. The number of apoptotic cells in each slide from at least five different fields was analyzed using Image-Pro Plus software (version 6.0 for Windows; Media Cybernetics, Inc., Rockville, MD, USA) with the assistance of a microscope (DM750; Leica Microsystems GmbH, Wetzlar, Germany). The number of positive cells was averaged for statistical analysis.

Liver immunohistochemistry. The paraffin sections were de-paraffinized and rehydrated. Endogenous peroxidase was inactivated by incubation in 0.3% hydrogen peroxide in absolute methanol for 30 min. The sections were incubated in 5% skim milk for 30 min at room temperature. Antigen retrieval was performed by microwave (700 W) treatment in 10 mM citrate buffer (pH 6.0) for 15 min. The sections were incubated overnight at 4°C with anti-PCNA primary antibody (Abcam) at a dilution of 1:500. Following washing with PBS, the sections were incubated at room temperature for 30 min in secondary antibody (Goat Anti-Rabbit; cat. no. ab205718; Abcam; 1:1,000). A brown color was developed with 3 diaminobenzidine for 2-4 min, and the sections were then washed in distilled water. The number of positively stained brown nuclei (denoting PCNA) in each slide from at least five different fields was analyzed using Image-Pro Plus software (version 6.0 for Windows) with the assistance of a microscope (DM750, Leica Microsystems GmbH). The number of positive cells was averaged for statistical analysis.

Cell culture and treatment. Human HepG2 cells, the HepG2 (ATCC HB 8065) cells were purchased from the Korea Cell Line Bank (Seoul, Korea), and were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% (v/v) heat-inactivated FBS and 1% penicillin and incubated in a humidified incubator with 5% CO₂, 95% air at 37°C. A dose of 5% hPH was used in the time-course investigation of the induction of antioxidant enzymes by hPH. To investigate the protective effects of hPH and its active mechanism on HepG2 cells challenged by D-GaIN (Sigma; EMD Millipore), the cells were pretreated with hPH for 2 h, stimulated with 50 mM D-GaIN at 37°C, and harvested for the indicated experiments.

Cell viability assay. The HepG2 cells, treated as described above, were further treated with 50 mM D-GaIN and incubated for another 24 h, following which the cell viability was determined using CCK-8 (Dojindo Molecular Technologies, Inc.). To determine cell viability, the HepG2 cells were seeded in 96-well plates at a density of 1x10⁴ cells/ml and grown for 24 h in a 37°C incubator. When the cells attained 70-80% confluence, they were either left untreated (control group) or treated with D-GaIN (50 mM), 5% hPH, or 5% hPH + D-GaIN (50 mM). Following incubation for 24 h, cell morphology changes were observed under Olympus inverted microscopes (Olympus Corporation, Tokyo, Japan). The supernatants were discarded, following which 10% CCK-8 solution in fresh DMEM (100 µl) were added to each well. The cells were then incubated at 37°C for 1 h, and the absorbance was measured at 450 nm directly in the wells using a SpectraMax i3x Multi-Mode detection platform (Molecular Devices LLC, Sunnyvale, CA, USA).

Measurement of LDH release. The LDH in the culture medium was assessed with 0.2 mM NADH and 0.4 mM pyruvic acid in up to 200 µl PBS at pH 7.4. The LDH concentration in the sample was proportional to the rate of NADH oxidation measured by absorbance at 334 nm (OD/min) using the SpectraMax i3x Multi-Mode detection platform. The LDH concentration in the culture media was calculated using a commercial standard LDH assay kit purchased from Abnova (cat. no. KA0785, Taipei, Taiwan).

DAPI staining. Morphological changes in the apoptotic cells were assessed by fluorescent microscopy following DAPI staining. Briefly, the HepG2 cells were seeded at a density of 1x10⁵ cells/ml in 6-well plates and grown for 24 h in a 37°C incubator. Following washing once with PBS, the cells were
either left untreated (control group) or treated with D-GalN (50 mM), 5% hPH, or 5% hPH + D-GalN (50 mM). Following incubation for 24 h, the cells were fixed in 4% formaldehyde for 1 h, and permeabilized with 0.1% Triton X-100 (Biosesang, Inc., Seongnam, Korea) for 5 min. Subsequently, DNA-specific fluorochrome DAPI (Invitrogen; Thermo Fisher Scientific, Inc.) was applied to each well, following which samples were incubated for 10 min in the dark at room temperature. Finally, the cells were washed three times with PBS and examined using a confocal microscope (Carl Zeiss AG, Oberkochen, Germany).

Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) staining and fluorescence images. For apoptotic cell analysis, the HepG2 (1x10^4/well) cultures in 96-well black plates were exposed to the indicated treatments for 12 h. The assay was performed according to the manufacturer's protocol (BD Biosciences, San Jose, CA, USA). Briefly, the cells were washed twice with PBS and again with binding buffer. Annexin V-fluorescein isothiocyanate and PI were added to each sample, and the mixture was incubated at room temperature for 15 min. The absorbance was read directly in the wells at 494/518 nm for FITC Annexin V and 535/617 nm for PI using the SpectraMax i3x Multi-Mode detection platform. The populations staining positive for Annexin V and PI were compared with the untreated group.

The HepG2 cells were grown to ~70% confluence; 1x10^5 cells were collected in a Petri dish and either left untreated (control group) or treated with D-GalN (50 mM), 5% hPH, or 5% hPH + D-GalN (50 mM), and then incubated for 24 h. The cells were then washed with PBS and stained with 10 µg/ml PI for 5 min, and fluorescent images were observed under a DP70 fluorescence microscope with DP Controller software (Olympus Corporation; ver. 3.2.276.2).

Measurement of ROS. Cytosolic and mitochondrial ROS were measured on a 96-well plate reader as previously described (28). Briefly, the HepG2 cells were seeded at a density of 1x10^5 cells/well on a white 96-well plate (Thermo Fisher Scientific, Inc.) and allowed to adhere overnight. Following seeding, the cells were washed and incubated with serum-starved medium, D-GalN (50 nM), 5% hPH, or 5% hPH + D-GalN (50 nM), and then incubated for 12 h at 37°C. The bound antibodies were detected using enhanced chemiluminescence (Amersham; GE Healthcare Life Sciences, Chalfont, UK). Images of the blotted membranes were captured using the LAS-1000 lumino-image analyzer (Fujifilm, Tokyo, Japan). The protein levels were compared to those of the appropriate loading control (GAPDH or non-phosphorylated proteins).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. Total RNA was extracted from the dorsal skin using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.). First-strand cDNA synthesis from the total RNA template was performed with PrimeScript RT master mix (Takara Bio, Inc., Tokyo, Japan). The resulting cDNA was subjected to real-time PCR (complementary cDNA, 2 µl; primer, 3 µl; 2X premix SYBR, 5 µl), using qPCR 2X PremIX SYBR (Enzymix, Seoul, Korea) and a CFX-96 thermocycler (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The PCR conditions used to amplify all genes were as follows: 10 min at 95°C and 40 cycles of 95°C for 10 sec, 60°C for 15 sec, and 72°C for 20 sec. The expression data were calculated from the quantification cycle (Cq) value using the ΔCq method of
quantification (30). GAPDH was used for normalization. The oligonucleotides that were used for qPCR were as follows: Human ATG8, forward 5'-CGCACCCTTGACCAAAAGA GT-3' and reverse, 5'-GACCATCCTGGGCGTGGTCT T-3'; human beclin 1 (BECN1), forward 5'-AACCTCACCGGA AGACTG A-3' and reverse, 5'-GCCTATGGCCAGCCTCT TT-3'; human cathepsin D (CTSD), forward 5'-CAAGTTCTGA TGCCCATCTGG-3' and reverse 5'-GGGTTGACATCCAG TAGGA-3'; human lysosomal-associated membrane protein 1 (LAMP1), forward 5'-CTTTCAAGGTTGAGGTGZG-3' and reverse 5'-GATAGCTGTAGCTGCGTG-3'; human activating transcription factor (ATF)6, forward 5'-GTGTCTGAGAAGAGAACGCT-3' and reverse 5'-GGTGCTCTCCTTT GATTCTGCA-3'; human ATF4, forward 5'-ACACCTCATCTG TTGAGCT-3' and reverse 5'-AGACACAGAGAACACC TG-3'; human C/EBP homologous protein (CHOP), forward 5'-CATGCGCTTCTTCTCCTCAGG-3' and reverse 5'-CCA GAGACAGGTGTCGA-3'.

Statistical analysis. All quantitative data are presented as the mean ± standard error of the mean for three independent experiments. Statistical analyses were performed using the statistical package for SPSS software version 17.0 (IBM Corp., Armonk, NY, USA). Differences between two groups were evaluated using a paired Student's t-test. For multiple comparisons, one-way analysis of variance was used followed by Tukey's multiple comparisons test. P<0.05 was considered to indicate a statistically significant difference.

Results

Effects of hPH on mortality rates of D-GalN/LPS-treated rats. Acute liver injury leads to high mortality rates in rats. Therefore, the present study assessed the effects of hPH on D-GalN (700 mg/gg)/LPS (15 μg/kg)-induced mortality. To investigate whether hPH can protect against liver injury in rats due to D-GalN/LPS, the survival rate of D-GalN/LPS + hPH-treated rats was monitored for 24 h (n=12). All saline-injected rats survived as the normal control group (n=12). No significant differences in gross liver examination, body weight, or liver weight were found between groups (Fig. 1A-C). As shown in Fig. 1D, a number of rats died 7 h following D-GalN/LPS injection, and the survival rate was 33.3% at 24 h. However, it was found that hPH pretreatment effectively increased the survival rate of rats with liver injury induced by D-GalN/LPS. Pretreatment with hPH (1.2 ml/kg) increased the survival rate to 83.3%, and all hPH (2.4 and 3.6 ml/kg)-treated rats survived. These results suggested that pretreatment with hPH effectively protected against D-GalN/LPS-induced mortality.

Effects of hPH on serum levels of ALT, AST, and inflammatory cytokines in LPS/D-GalN-induced liver failure in rats. The serum levels of ALT, AST, LDH, and inflammatory cytokines are well-established markers of hepatic injury (31). In order to investigate the effects of hPH on D-GalN/LPS-induced liver damage, hematological tests were performed. Serum (n=4-6) was collected to detect AST, ALT, LDH, IL-6, and TNF-α. As shown in Fig. 1E-G, LPS/D-GalN markedly increased serum levels of AST, ALT, and LDH, whereas hPH reduced these elevations. As hepatocyte injury resulting from acute liver injury is accompanied by an elevation in inflammatory cytokines (32), the present study examined the effect of hPH on hepatotoxicity by measuring serum levels of IL-6 and TNF-α (Fig. 1H and I). The D-GalN/LPS-treated rats exhibited significant increases in levels of IL-6 and TNF-α compared with normal rats. In addition, hPH pretreatment significantly inhibited the release of these pro-inflammatory cytokines compared with the LPS/D-GalN group. These results suggested that hPH effectively protected against LPS/D-GalN-induced liver degeneration and inflammatory responses.

Effects of hPH on hepatotoxicity of hepatocytes. The present study also investigated histological changes following liver injury to confirm the protective effects of hPH. The rats treated with D-GalN/LPS showed severe histopathological degeneration evidenced by severe intrahepatic hemorrhaging, apoptosis, necrosis, ballooned hepatocytes, and hepatocytes expanded by fat vacuoles, whereas hPH (1.2, 2.4 and 3.6 ml/kg) treatment ameliorated these changes (Fig. 2A). It has been suggested that D-GalN/LPS-induced imbalance between apoptosis and proliferation in hepatocytes is responsible for the impairment of liver function. Therefore, hPH-mediated modulations of proliferation (PCNA) and apoptosis (TUNEL) were also evaluated by immunohistochemical analysis (Fig. 2B and C). A high expression of PCNA and low numbers of TUNEL-positive cells were observed in the control group. However, D-GalN/LPS markedly reduced PCNA immunoreactivity and significantly increased the number of apoptotic cells. By contrast, pre-administration of hPH resulted in an increase of PCNA-positive cells and reduced the number of apoptotic cells in all three dose groups. Graphs showing results of the staining experiments are shown in Fig. 2D-F. These observations indicated that hPH pretreatment ameliorated hepatic injury by reducing D-GalN/LPS-induced hepatocyte damage in rats.

hPH protects hepatocytes against D-GalN-induced apoptosis. Hepatocyte apoptosis is important in the pathogenesis of liver disease, including ALF (33). D-GalN induces hepatocyte cell death in vivo (34) and in vitro (35); it offers a suitable experimental model based on its capacity to reduce the intra-cellular pool of uridine monophosphate in hepatocytes, inhibiting the synthesis of RNA and proteins, and leading to cell apoptosis. Therefore, the present study investigated whether D-GalN-induced hepatotoxicity occurred in HepG2 cells. Following D-GalN stimulation, cell viability decreased markedly in a dose-dependent manner. The results revealed a reduction of 50% at 50 mM D-GalN and of 82% at 100 mM D-GalN in the HepG2 cells (Fig. 3A). The cytotoxic effects of hPH on HepG2 cells have not been examined previously. The present study used a CCK-8 assay to evaluate the dose-dependent cytotoxic effects of hPH on HepG2 cells. The results showed that stimulation with hPH had no significant effect on cell viability at various concentrations (1.25-5% in serum-free DMEM) over 24 h. Therefore, hPH was used at a concentration of 5% in subsequent experiments (Fig. 3B). In addition to the D-GalN-induced decrease in cell viability being attenuated by pretreatment with hPH, the concentration of LDH released from the hepatocytes was also reduced in the D-GalN + 5% hPH-stimulated cells, compared with the
These results indicated that hPH protected against D-GalN-induced hepatotoxicity in HepG2 cells. Changes in cellular morphology and cell viability were also evaluated to examine the protective effects of hPH in D-GalN-stimulated HepG2 cells. As shown in Fig. 3E, the D-GalN-stimulated HepG2 cells exhibited a marked reduction in the number of hepatocytes. However, hPH pretreatment effectively improved the D-GalN-mediated cell damages.

To examine the inhibitory mechanisms of hPH in D-GalN-induced cytotoxicity, the HepG2 cells were assessed by Annexin V and PI staining, followed by microplate analysis (Fig. 3F and G) or fluorescence microscopy (Fig. 3H). D-GalN stimulation alone facilitated the induction of apoptosis, including levels of Annexin V⁺ (841%)/PI⁺ (948%), compared with the controls. By contrast, pretreatment with hPH significantly inhibited D-GalN-induced apoptosis (Annexin V⁺, 801%; PI⁺, 280%). D-GalN-induced DNA fragmentation was also effectively attenuated by hPH pretreatment (Fig. 3H). The present study further examined whether hPH regulated PARP-dependent cell death. D-GalN induced an increase of Bax (pro-apoptotic protein) and a decrease of Bcl-2 (anti-apoptotic protein) (Fig. 3I and J). Furthermore, the cleavage of PARP was inhibited in the HepG2 cells by pretreatment with hPH (Fig. 3I and J). These findings suggested that hPH treatment significantly improved hepatocyte degeneration through the attenuation of apoptosis in HepG2 cells.

hPH regulates D-GalN-mediated intracellular ROS generation and mitochondrial dysfunction. The rapid generation of...
ROS is associated with hyperpolarization of the mitochondrial membrane potential and apoptosis in d-GalN-treated hepatocytes (36). In addition, d-GalN-dependent cell necrosis is associated with mitochondrial membrane depolarization (37). To investigate whether the D-GalN-mediated increase in abnormal mitochondria was rescued by hPH treatment, the present study first evaluated mitochondrial morphology using Tomm20 (mitochondrial outer membrane) staining (Fig. 4A). Mitochondrial morphology was altered at 24 h in the d-GalN-stimulated HepG2 cells. However, the increased mitochondrial damage was attenuated significantly by hPH. In addition, mitochondrial mass decreased, by ~55%, in the d-GalN-stimulated HepG2 cells, and this was rescued by hPH pretreatment (Fig. 4B).

ΔΨm was then evaluated using microplate analysis. The d-GalN-stimulated HepG2 cells exhibited decreased ΔΨm; however, this decrease was significantly attenuated in the hPH-pretreated cells and unstimulated cells (Fig. 4C). These findings suggested that hPH improved D-GalN-mediated mitochondrial dysfunction by improving ΔΨm and inhibiting quantitative mitochondria loss.

Subsequently, the present study determined whether hPH was involved in the negative regulation of oxidative stress. The HepG2 cells were stimulated with D-GalN in the presence or absence of hPH, and ROS generation was determined using DCFH-DA or MitoSOX (mitochondrial-specific superoxide indicator) (38) as a probe for microplate analyses (Fig. 4D and E). D-GalN alone led to the potent intracellular generation of ROS, whereas the D-GalN-induced generation of ROS in HepG2 cells was attenuated significantly by hPH pretreatment (Fig. 4D). Mitochondrial ROS increased...
significantly following treatment with D-GalN (Fig. 4E), whereas D-GalN-induced mitochondrial ROS generation was decreased by pretreatment with hPH. These results suggested that hPH protected against D-GalN-mediated...
apoptotic cell death by regulating the generation of cytosolic and mitochondrial ROS.

**hPH regulates expression of antioxidant enzymes in HepG2 cells.** As the induction of antioxidant enzymes is a universal stress response against liver degeneration and has been widely shown to have an anti-apoptotic effect, the expression levels of antioxidative enzymes SOD1, SOD2, GPx, and catalase were detected by western blot analysis (Fig. 5A). hPH induced antioxidative enzyme expression in the HepG2 cells. These enzymes were elevated 1 h following hPH treatment and were maintained at this level until 8 h. Furthermore, to investigate the antioxidant mechanisms of hPH, Nrf2 pathway-related gene expression on HepG2 cells was evaluated (Fig. 5B-d). The induction of Nrf2 upregulates antioxidant proteins, including SOD, catalase, and HO-1, reducing ROS (13). hPH treatment resulted in a significant decrease of Keap1 at 4-8 h. However, hPH increased the protein levels of cytoplasmic p-p62 and HO-1. Additionally, p62 was upregulated 4-8 h following hPH treatment (Fig. 5B). Furthermore, the expression of Nrf2 was decreased in the cytosol and increased in the nucleus (active Nrf2) following hPH treatment, indicating that translocation to the nucleus was affected by hPH treatment (Fig. 5C and D). Together, these findings indicated that the induction of antioxidative enzymes by hPH treatment was modulated by the Keap1-p62-Nrf2 pathway.

**hPH minimizes the expression of damage-related molecules via the regulation of autophagy.** Autophagy, mitochondria, and oxidative stress are closely intertwined in redox signalling (39). Additionally, D-GalN-induced cell damage regulates the autophagy process in early stages. To investigate whether the regulation of autophagy is influenced by D-GalN stimulation and the effects of hPH, the present study measured the level of autophagy regulation by staining cells with anti-LC3 II antibody (Fig. 6A). LC3 II is an established autophagy marker due to its involvement in autophagosome membrane formation (40). In the present study, compared with the cells treated with vehicle control or D-GalN alone, the cells treated with hPH exhibited significantly fewer LC3 puncta per cell (Fig. 6A). The changes in autophagy-related genes were then quantified through assessment of RNA and protein levels in the hPH-treated HepG2 cells. As shown in Fig. 6B and C, hPH treatment induced a decrease in the conversion of LC3-I to LC3-II (lipidated form), the latter of which is a reliable marker of autophagosome generation. Furthermore, the expression levels of DRAM, CHOP, and p53 (proteins associated with autophagic cell death) indicated that a minimized autophagy process was induced in the hPH-treated cells (Fig. 6B) (20,41,42). Similarly, the transcription levels of autophagy-related genes (ATG8, CTSD, BECN1, and LAMP1) and of ER stress-related genes (ATF4, ATF6, and CHOP) were lower in the hPH-treated cells compared with those in cells treated with D-GalN only (Fig. 6C). These results suggested that hPH treatment minimized the escalation of D-GalN-induced autophagy processes in HepG2 cells.

**Discussion**

Apoptosis and oxidative stress are interrelated biological events that are involved in the pathogenesis of various diseases, including ALF (43-46). Emerging evidence suggests that D-GalN/LPS-induced oxidative stress gives rise to hepatic injuries resulting from oxidative stress and apoptosis, which parallel those of liver degeneration (6,7).
In addition, D-GalN/LPS-induced ALF is widely accepted as an experimental liver injury animal model, contributing to investigation of the mechanisms underlying clinical liver injury and the development of efficient hepatoprotective materials (47-51). Accordingly, any approach that relieves apoptosis and oxidative stress in vitro and in vivo contributes to the prevention or treatment of ALF. In the present study, it was demonstrated that pretreatment with hPH attenuated acute liver injury associated with elevated serum levels of ALP, AST, LdH, and pro-inflammatory cytokines (IL-6 and TNF-α). Furthermore, it was found that apoptosis was increased following d-GalN/LPS injection, whereas pretreatment with hPH effectively inhibited tissue degeneration and increased cell death in d-GalN/LPS-induced acute liver injury. Pretreatment with hPH also reversed the extensive vacuolization, severe intrahepatic hemorrhage, destruction of nuclei, and loss of hepatic cords. Consistently, it has been reported that hPH possesses a variety of biological activities, including anti-inflammatory (26,52-56) and antioxidant (26,57-59) properties. Exposure to hazardous components from the environment can lead to pregnancy loss, uterine dysfunction, or fetal death (60). It has been reported that oxidative stress is mainly or partly involved in damage from these harmful environments (61). Therefore, the human placenta contains antioxidant defense substances to protect embryos from oxidative stress (62-64). In the present study, human placenta extract prepared from the placenta of healthy pregnant females is known to have various physiological actions, including antioxidative properties (57,65). In the present study, hPH was prepared with human placenta, including umbilical cord, following the provision of consent from the pregnant women. The hydrolysate of human placenta is manufactured by a chemical process with Hcl and pepsin, followed by dialysis, heat treatment and hydrolysis. This hydrolysate contains various amino acids, including arginine (0.08%), lysine (0.1%), phenylalanine (0.08%), tyrosine (0.03%), leucine (0.12%), methionine (0.03%), valine (0.04%), alanine (0.08%), serine (0.07%), and threonine (0.06%). Based on this, hPH is considered to contain the cleaved proteins of the amino acids and their active ingredients.

In previous studies, it has been reported that D-GalN leads to cytotoxicity and apoptotic cell death in HepG2 cells (66-68). D-GalN/LPS intoxication causes an imbalance between pro-oxidants and antioxidants, involving the excessive production of ROS and a deficiency of cellular antioxidants, including glutathione, catalase and SOd. Oxidative stress caused by D-GalN/LPS is a recognized phenomenon in liver damage (47,69-71). In addition, D-GalN/LPS induces loss of ΔΨm and production of ROS, resulting in liver damage (36,72-74). Mitochondria are the major subcellular organelles responsible for ROS production (75). The results of the present study demonstrated that hPH enhanced the expression of SOD-1, SOD-2, catalase and GPx, and increased the nuclear translocation of the Nrf2 via a Keap1-p62-Nrf2 mechanism. The upregulation of various important antioxidants is caused by the binding of Nrf2 to the ARE of...
antioxidant target proteins, including SOD, catalase, NQO1, GCLM and HO-I (15,16). Nrf2 has been regarded as a novel therapeutic target for the treatment of liver disease (76-80). In Nrf2-deficient mice, the expression of various cytoprotective enzymes was decreased in hepatocytes, resulting in oxidative stress and markedly delayed liver regeneration (81). In addition, genetic disruption of Nrf2 triggers the progression of necroinflammation and hepatic fibrosis in Hfe-/- mice presenting with no liver injury (82). Pretreatment with sulforaphane prevents hepatic damage induced by intestinal ischemia/reperfusion in rats through an antioxidative effect via the Nrf2-ARE pathway (79). Another study showed that the expression of Nrf2 was upregulated to protect the liver from inflammatory damage caused by oxidative stress during the development of non-alcoholic fatty liver and steatohepatitis (78). Additionally, Farombi et al reported that curcumin (diferuloylmethane) administration promoted the nuclear translocation and ARE-binding of Nrf2, leading to prevention of dimethylnitrosamine-induced hepatotoxicity (76). In addition, β-cryptoxanthin was found to ameliorate visceral fat and cardiometabolic health risk factors by modulating the expression of nuclear factor-κB and Nrf2 in rats fed a high-fat diet (83).

Autophagy is an evolutionarily conserved homeostatic process and lysosome-dependent proteolytic pathway, which is involved in a variety of physiological and pathological
processes (84,85). According to previous data, autophagy is involved in major liver diseases, including liver ischemia/reperfusion injury, hepatitis B and C, hepatocellular carcinoma, alcoholic liver disease and non-alcoholic fatty liver disease (86). In addition, autophagy is induced to maintain healthy cells in the presence of TNF-α, acetalaminophen-, or ethanol-induced liver injury (87-89). However, excessive autophagy can cause autophagic cell death. Previously, autophagy has been shown to be elevated in concanavalin A-induced acute hepatitis, leading to the autophagic cell death of hepatoma cells in SCID/NOD mice (90). Furthermore, autophagy inhibition significantly improved liver graft dysfunction and the survival rate of recipient rats with ‘cold ischemia-warm reperfusion injury’ associated with liver transplantation (91), suggesting that autophagy can aggravate liver damage. In the present study, it was found that excessive autophagy was induced following D-GalN administration, and that pretreatment with hPH effectively suppressed this enhanced autophagy in D-GalN-induced HepG2 cells. It also indicated a regulatory pathway mechanism of autophagy induction and inhibition by D-GalN/hPH via the p53-DRAM-autophagy axis. The identification of DRAM as a p53 target mediating the induction of autophagy allowed for investigation of the role of autophagy in apoptosis (42). Liu et al reported that p53-induced apoptosis is primarily dependent on DRAM- and BAX-mediated autophagy in hepatosteatosis in oleic acid-treated HepG2 cells and high-fat diet mice (92). The induction of autophagy by the nuclear translocation of p53 involves the upregulation of DRAM and sestrin2 in p53-sufficient, but not in p53-deficient cells (93). The expression of CHOP is regulated transcriptionally and post-transcriptionally in hPH-induced HepG2 cells. CHOP, a multifunctional transcription factor in the ER stress response, promotes autophagic apoptosis induced by various stimuli, including tetrahydrocannabinol, 2-deoxy-D-glucose, rabbit hemorrhagic disease virus, and apoptosis-stimulating protein of p53-2 (94-97). The data obtained in the present study also demonstrated that hPH led to downregulation of the ER stress-related downstream targets, ATF4 and ATF6, in D-GalN-treated HepG2 cells. Based on the above findings, it was concluded that autophagy, apoptosis and ER stress are closely associated with each other, supported by the results of the present study. D-GalN stimulation increased the expression levels of DRAM, CHOP and the apoptosis-related protein p53 in HepG2 cells, whereas hPH pretreatment reversed the expression of these proteins. hPH pretreatment also resulted in LC3 lipidation, but meaningfully minimized autophagosome expression compared with D-GalN alone.

In previous animal studies, early onset autophagy has been shown to increase liver injury, however, this observation has not been corroborated in patient populations. Therefore, the epidemiological relevance of autophagy and liver damage require investigation in the future. Taken together, the results of the present study showed that hPH had a protective effect on hepatocyte apoptosis through antioxidative modulation and minimization of the autophagy process, which resulted in the inhibition of hepatocytotoxicity. This may be useful as a target for the treatment of acute liver injury. The identification of this pathway can assist in understanding the molecular events leading to the activation of oxidative stress- and autophagy-mediated cell death in human disease, and contribute to the design of novel therapeutic strategies for inhibiting liver disease and preventing fulminant hepatic failure.

Acknowledgements

Not applicable.

Funding

This study was supported by Green Cross WellBeing Corporation, Korea (grant no. 20161015) and by the Chung-Ang University Research Scholarship Grants in 2017.

Availability of data and materials

The analyzed data sets generated during the study are available from the corresponding author on reasonable request.

Authors’ contributions

BJK, THK, DHB, JN, and MJc designed experiments; DHB, JN, and MJC performed experiments; MJK, BCL, THK, DHB, JN, MJC, CTO, JYK, and HJH analyzed data; CTO, JYK, and HJH prepared materials; DHB, JN, and MJC prepared figures; BJK, THK, DHB, and JN wrote the manuscript. BJK and THK had primary responsibility for final content. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the Institutional Animal Care and Use Committee of Chung-Ang University (2017-00003). Placental tissues were used following the provision of informed consent from the pregnant women.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Bernal W, Auzinger G, Dhawan A and Wendon J: Acute liver failure. Lancet 376: 190-201, 2010.
2. Han DW: Intestinal endotoxemia as a pathogenetic mechanism in liver failure. World J Gastroenterol 8: 961-965, 2002.
3. Sathivel A, Balavinayagamani, Hanumantha Rao BR and Devaki T: Sulfated polysaccharide isolated from Ulva lactuca attenuates d-galactosamine induced DNA fragmentation and necrosis during liver damage in rats. Pharm Biol 52: 498-505, 2014.
4. Masaki T, Chiba S, Tatsukawa H, Yasuda T, Noguchi H, Seike M and Yoshimatsu H: Adiponectin protects LPS-induced liver injury through modulation of TNF-α in KK-Ay obese mice. Hepatology 40: 177-184, 2004.
5. Wu Z, Han M, Chen T, Yan W and Ning Q: Acute liver failure: Mechanisms of immune-mediated liver injury. Liver Int 30: 782-794, 2010.
16. Jian Z, Ibrahím S, Devaí K, Chakraborty S, Agarwal S and Pérez-Sánchez H: Lycopepein prevents mitochondrial dysfunction during d-galactosamine/lipopolysaccharide-induced fulminant hepatic failure in albinó rats. J Proteome Res 17: 3190-3197, 2017.

15. Bataille A and Manautou J: Nrf2: A potential target for new therapeutics in liver disease. Clin Pharmacol Ther 92: 340-348, 2017.

14. Lee SB, Kang JW, Kim SJ, Ahn J, Kim J and Lee SM: Afzelin ameliorates D-galactosamine and lipopolysaccharide-induced fulminant hepatic failure by modulating mitochondrial quality control and dynamics. Br J Pharmacol 174: 195-209, 2017.

13. Decker CW, Cianci G, Khan AT, Horton LA, Rao MP, Silim AAH and Harbin D: The critical role of mitochondria in drug-induced liver injury. In: Molecules, Systems and Signaling in Liver Injury. Springer, pp159-181, 2017.

12. Nguyen T, Nioi P and Pickett CB: The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 284: 13291-13295, 2009.

11. Tonello G, Dallo M, Zaccarelli N, Sottofattori E, Mazzei M and Fedele M: Mitochondrial Peptide 126: 121-134, 2006.

10. Santos-Gonzalez M, Lopez-Lluch G, Briceño J, Gómez MA, Poyato A, et al.: N-acetylcysteine, coenzyme Q10 and superoxide dismutase mimetic protect mitochondrial function and cell death induced by d-galactosamine in primary culture of human hepatocytes. Chem Biol Interact 181: 95-106, 2009.

9. Zhao Y, Li S, Childs EE, Kuharsky DK and Yin XM: Activation of pro-death Bcl-2 family proteins and mitochondria apoptosis pathway in tumor necrosis factor-α-induced liver injury. J Biol Chem 276: 27432-27440, 2001.

8. Kuznetsov AV, Kehrer I, Kozlov AV, Haller M, Redl H, Hermann M, Grimm M and Troppmair J: Mitochondrial ROS production under cellular stress: Comparison of different detection methods. Anal Bioanal Chem 400: 2383-2390, 2011.

7. Lee J, Giordano S and Zhang J: Autophagy fights disease through cellular self-digestion. Nature 451: 1069-1075, 2008.

6. Jenner P: Oxidative stress in Parkinson's disease. Ann Neurol 53: 149-156, 2003.

5. Kuznetsov AV, Kehrer I, Kozlov AV, Haller M, Redl H, Hermann M, Grimm M and Troppmair J: Mitochondrial ROS production under cellular stress: Comparison of different detection methods. Anal Bioanal Chem 400: 2383-2390, 2011.

4. Nowak M, Gaines GC, Rosenberg JA, Minter R, Bahjat FR, Yoshikawa T: Rosmarinic acid, a major polyphenolic component of *Rosmarinus officinalis*, reduces lipopolysaccharide (LPS)-induced liver injury in D-galactosamine (D-GalN)-sensitized mice. Free Radic Biol Med 30: 879-887, 2001.

3. Kojima H, Ito T, Takeuchi K, Hase S, Kobayashi M, Hasegawa T, et al.: Mitochondrial Peptide 126: 121-134, 2006.

2. Lee J, Giordano S and Zhang J: Autophagy, mitochondria and oxidative stress: Cross-talk and redox signalling. Biochem J 441: 523-540, 2012.

1. Yang Z and Kjellman I: Mammalian autophagy: Core molecular machinery and signaling regulation. Curr Opin Cell Biol 22: 124-131, 2010.

0. Kojima H, Ito T, Takeuchi K, Hase S, Kobayashi M, Hasegawa T, et al.: Mitochondrial Peptide 126: 121-134, 2006.

__**INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE** 42: 2569-2583, 2018__

6. Sherriff SA, Shaik Ibrahim S, Devaí K, Chakraborty S, Agarwal S and Pérez-Sánchez H: Lycopepein prevents mitochondrial dysfunction during d-galactosamine/lipopolysaccharide-induced fulminant hepatic failure in albinó rats. J Proteome Res 17: 3190-3197, 2017.

5. Dong L, Yin L, Quan H, Chu Y and Lu J: Hepatoprotective effects of kaempferol-3-O-α-l-rhamnosylpyranosyl-7-O-α-L-rhamnopyranoside on d-Galactosamine and lipopolysaccharide caused hepatic failure in mice. Molecules 22: E1755, 2017.

4. Lee SB, Kang SM, Ahn J, Kim J and Lee SM: Afzelin ameliorates D-galactosamine and lipopolysaccharide-induced fulminant hepatic failure by modulating mitochondrial quality control and dynamics. Br J Pharmacol 174: 195-209, 2017.

3. Decker CW, Cianci G, Khan AT, Horton LA, Rao MP, Silim AAH and Harbin D: The critical role of mitochondria in drug-induced liver injury. In: Molecules, Systems and Signaling in Liver Injury. Springer, pp159-181, 2017.

2. Nguyen T, Nioi P and Pickett CB: The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 284: 13291-13295, 2009.

1. Bryan HK, Olayanju A, Goldberg CE and Park BK: The Nrf2 cell defence pathway: Keap1-dependent and-independent mechanisms of regulation. Biochem Pharmacol 85: 705-717, 2013.
50. Chen L, Ren F, Zhang H, Wen T, Piao Z, Zhou L, Zheng S, Zhang J, Chen Y, Han Y, et al: Inhibition of glycosyn thase kinase 3β mediates ameliorates D-GalN/LPS-induced liver injury by reducing endoplasmic reticulum stress-triggered apoptosis. PLoS One 7:e45202, 2012.

51. Wang H, Xu DX, Lv JW, Ning H and Wei W: Melatonin attenuates lipopolysaccharide (LPS)-induced apoptotic liver damage in D-galactosamine-sensitized mice. Toxicology 237: 49-57, 2007.

52. Kawakatsu M, Ura ta Y, Goto S, Ono Y and Li TS: Placental extract protects bone marrow-derived stem/progenitor cells against radiation injury through an anti-inflammatory activity. J Radiat Res 54: 268-276, 2012.

53. Park JY, Lee J, Jeong M, Min S, Kim SY, Lee H, Lim Y and Park HJ: Effect of Hominsis Placenta on cutaneous wound healing in diabetic mice. Nutri Res Pract 8: 404-409, 2014.

54. Lee KH, Kim TH, Lee WK, SH Lee and Lee SM: Anti-inflammatory and analgesic effects of human placenta extract. Nat Prod Res 25: 1090-1100, 2011.

55. Lee KW, Ji HM, Kim DW, Choi SM, Kim S and Yang EJ: Effects of Hominsis placenta on LPS-induced cell toxicity in BV2 microglial cells. J Ethnopharmacol 147: 286-292, 2013.

56. Akagi H, Imamura Y, Makita Y, Nakamura H, Hasegawa N, Fujiwara SI and Wang PL: Evaluation of collagen type-1 production and anti-inflammatory activities of human placental extracts in human gingival fibroblasts. J Hard Tissue Biol 25: 277-281, 2016.

57. Watanabe S, Togashi N, Takahashi M, Iwama M, Watanabe S, Tamagawa K and Togashi SI, Takahashi N, Iwama M, Watanabe S, Tamagawa K: Participation of the PKCα/RIPK3/BAK1 pathway in the induction of cell death by high-fat diet in rodents. Food Chem Toxicol 107: 119-126, 2017.

58. Togashi SI, Takahashi N, Iwama M, Watanabe S, Tamagawa K and Togashi SI, Takahashi N, Iwama M, Watanabe S, Tamagawa K: Participation of the PKCα/RIPK3/BAK1 pathway in the induction of cell death by high-fat diet in rodents. Food Chem Toxicol 107: 119-126, 2017.

59. Wells PG and Winn LM: Biochemical toxicology of chemical teratogenesis. Crit Rev Biochem Mol Biol 31: 1-40, 1996.

60. Avisson N, Whitin JC, Allen PZ, Wagner DD, Liegey P and Wagner DD: Antioxidative defence mechanisms against reducing endoplasmic reticulum stress-triggered apoptosis. PLoS ONE 7:e45202, 2012.

61. Akagi H, Imamura Y, Makita Y, Nakamura H, Hasegawa N, Fujiwara SI and Wang PL: Evaluation of collagen type-1 production and anti-inflammatory activities of human placental extracts in human gingival fibroblasts. J Hard Tissue Biol 25: 277-281, 2016.

62. Avissar N, Whitin JC, Allen PZ, Wagner DD, Liegey P and Wagner DD: Antioxidative defence mechanisms against reducing endoplasmic reticulum stress-triggered apoptosis. PLoS ONE 7:e45202, 2012.

63. Thomas EL, Learn DB, Jefferson MM and Weathered W: Mitochondria-mediated apoptosis in response to oxidative stress in human erythrocytes. J Cell Mol Biol Lett 17: 466-472, 2001.

64. Kankofer M: Antioxidative defence mechanisms against reducing endoplasmic reticulum stress-triggered apoptosis. PLoS ONE 7:e45202, 2012.

65. Fukushima T, Kikuchi T, Tsuchida K and Tomita M: Nrf2 expression in non-alcoholic fatty liver and steatohepatitis. J Mol Biol Lett 17: 240-248, 2012.

66. González R, Collado JA, Nell S, Briceño J, Tamayo MJ, Fraga E, Bernardos A, López-Cillero P, Pascussi JM, Rufián S, García J, Cadenas E, Bernardo P, Bernardi P, Chang C, Yoshida Y, Higuchi M, Koga Y, Ozawa T and Tajima HJ: Evaluation of ROS generation by intestinal ischemia reperfusion through Nrf2-ARE pathway. World J Gastroenterol 16: 3002-3010, 2010.

67. Pan CW, Pan ZZ, Hu JJ, Chen WL, Zhou GY, Lin W, Jin LX and Xu CL: Mangiferin alleviates lipopolysaccharide and D-galactosamine-induced acute liver injury by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation. Eur J Pharmacol 770: 85-91, 2016.

68. Donohue TM Jr: Autophagy and ethanol-induced liver injury. Crit Rev Biochem Mol Biol 31: 1-40, 1996.

69. Wang Y, Li Y, Xie J, Zhang Y, Wang J, Sun X and Zhang H: α-lipoic acid in LPS/d-GalN induced fulminant hepatic failure in mice. J Surg Res 137: 217-223, 2007.

70. Mahmoud MF, Hamdan DI, Wink M and El-Shazly AM: Curcumin attenuates dimethylnitrosamine-induced liver injury in rats through Nrf2-mediated induction of heme oxygenase-1. J Exp Clin Cancer Res 27: 129, 2008.

71. Klaassen CD and Reisman SA: Nrf2 the rescue: Effects of the antioxidant/electrophilic response on the liver. Toxicol Appl Pharmacol 244: 57-65, 2010.

72. Xu W, Shao L, Zhou C, Wang H and Guo J: Upregulation of Nrf2 expression in non-alcoholic fatty liver and steatohepatitis. Hepatogastroenterology 58: 2582-2586, 2011.

73. Zhao HJ, Zhang F, Chen G, Li YB, Li YH, Jing HR, Ma LF, Yao JH and Tian XF: Sulforaphane protects liver injury induced by ischemia reperfusion through Nrf2-ARE pathway. World J Gastroenterol 16: 3002-3010, 2010.

74. Mahmoud MF, Hamdan DI, Wink M and El-Shazly AM: Curcumin attenuates dimethylnitrosamine-induced liver injury in rats through Nrf2-mediated induction of heme oxygenase-1. J Exp Clin Cancer Res 27: 129, 2008.

75. Indo HP, Davidson M, Yen HC, Suenaga S, Tomita K, Nishi T, Higuchi M, Koga Y, Ozawa T and Tajima HJ: Effects of ROS generation by intestinal ischemia reperfusion through Nrf2-ARE pathway. World J Gastroenterol 16: 3002-3010, 2010.

76. Pan CW, Pan ZZ, Hu JJ, Chen WL, Zhou GY, Lin W, Jin LX and Xu CL: Mangiferin alleviates lipopolysaccharide and D-galactosamine-induced acute liver injury by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation. Eur J Pharmacol 770: 85-91, 2016.

77. Beyer TA, Xu W, Teupser D, auf dem Keller U, Bugnon P, Hildt E, Thiery J, Kan YW and Werner S: Impaired liver regeneration in Nrf2 knockout mice: Role of ROS-mediated insulin/IGF-1 resistance. EMBO J 27: 212-223, 2008.

78. Duarte TL, Caldas C, Santos AG, Silva-Gomes S, Santos-Gonçalves A, Martins MJ, Porto G and Lopes JM: Genetic disruption of Nrf2 promotes the development of necroinflammation and liver fibrosis in a mouse model of HFE-hereditary hemochromatosis. Redox Biol 11: 157-169, 2017.

79. Sahin K, Orhan C, Akdemir F, Tuzcu M, Sahin N, Yilmaz I and Futurer V: β-Cryptoxanthin ameliorates metabolic risk factors by regulating NF-κB and Nrf2 pathways in insulin resistance induced by high-fat diet in rodents. Food Chem Toxicol 107: 270-279, 2017.

80. Choi AM, Ryter SW and Levine B: Autophagy in human health and disease. N Engl J Med 368: 651-662, 2013.

81. Uchiyama Y, Shibata M, Koike M, Yoshimura K and Sasaki M: Autophagy-physiology and pathophysiology. Histochem Cell Biol 129: 407-420, 2008.

82. Rautou PE, Mansouri A, Llebre C, Durand F, Valla D and Moreau R: Autophagy in liver diseases. J Hepatol 53: 1123-1134, 2010.

83. Chiririr M, Zhao E, Fontana L, Rosenberg H, Tanaka K, Gao G and Czaja MJ: Impaired liver regeneration in mice. J Hepatol 61: 825-831, 2014.

84. Chiririr M, Zhao E, Fontana L, Rosenberg H, Tanaka K, Gao G and Czaja MJ: Impaired liver regeneration in mice. J Hepatol 61: 825-831, 2014.

85. Donohue TM Jr: Autophagy and ethanol-induced liver injury. World J Gastroenterol 15: 1178-1185, 2009.

86. Lin Z, Wu F, Lin S, Pan X, Jin L, Lu T, Shi L, Wang Y, Xu A and Liao X: Apoptotic effects against acetaminophen-induced mitochondrial dysfunction and acute liver injury by promoting autophagy in mice. J Hepatol 61: 825-831, 2014.

87. Chang CP and Lei HY: Autophagy induction in T cell-independent acute hepatitis induced by concanavalin A in SCID/NOD mice. Int Immunopharmacol Pharmacol 21: 817-826, 2008.

88. Gotoh K, Lu Z, Morita M, Shibata M, Koike M, Waguiri S, Ono K, Doki Y, Sotaniwa E, Sugioka A, et al: Participation of autophagy in the initiation of graft dysfunction after rat liver transplantation. Autophagy 5: 351-360, 2009.
92. Liu K, Lou J, Yin J, Xu B, Ding W, Wang A, Liu D, Zhang C, Chen D and Li N: Depending on the stage of hepatosteatosis, p53 causes apoptosis primarily through either DRAM-induced autophagy or BAX. Liver Int 33: 1566-1574, 2013.

93. Maiuri MC, Malik SA, Morselli E, Kepp O, Criollo A, Mouchel PL, Carnuccio R and Kroemer G: Stimulation of autophagy by the p53 target gene Sestrin2. Cell Cycle 8: 1571-1576, 2009.

94. Salazar M, Carracedo A, Salanueva IJ, Hernández-Tiedra S, Lorente M, Egia A, Vázquez P, Blázquez C, Torres S, García S, et al: Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest 119: 1359-1372, 2009.

95. Xi H, Kurtoglu M, Liu H, Wangpaichitr M, You M, Liu X, Savaraj N and Lampidis TJ: 2′-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion. Cancer Chemother Pharmacol 67: 899-910, 2011.

96. Liu K, Shi Y, Guo X, Wang S, Ouyang Y, Hao M, Liu D, Qiao L, Li N, Zheng J and Chen D: CHOP mediates ASPP2-induced autophagic apoptosis in hepatoma cells by releasing Beclin-1 from Bcl-2 and inducing nuclear translocation of Bcl-2. Cell Death Dis 5: e1323, 2014.

97. Tuñón MJ, San-Miguel B, Crespo I, Lalíena A, Vallejo D, Alvarez M, Prieto J and González-Gallego J: Melatonin treatment reduces endoplasmic reticulum stress and modulates the unfolded protein response in rabbits with lethal fulminant hepatitis of viral origin. J Pineal Res 55: 221-228, 2013.